David Morris, MD, FACS, shares advice on followup with patients on androgen deprivation therapy for prostate cancer.
January 2023 AbbVie Inc. Company Confidential
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.